SPY391.86-16.46 -4.03%
DIA315.55-11.55 -3.53%
IXIC11,418.15-566.37 -4.73%

BRIEF-180 Life Sciences And University Of Oxford Announce Publication Of Positive Phase 2B Dupuytren's Disease Study Results In Lancet Rheumatology

reuters.com · 04/29/2022 18:37
BRIEF-180 Life Sciences And University Of Oxford Announce Publication Of Positive Phase 2B Dupuytren's Disease Study Results In Lancet Rheumatology

- 180 Life Sciences Corp ATNF:

  • 180 LIFE SCIENCES AND UNIVERSITY OF OXFORD ANNOUNCE PUBLICATION OF POSITIVE PHASE 2B DUPUYTREN’S DISEASE STUDY RESULTS IN THE LANCET RHEUMATOLOGY

  • SAYS STUDY ACHIEVED PRIMARY ENDPOINT OF REDUCTION IN NODULE HARDNESS AT 12 MONTHS

  • TREATMENT ARM SHOWED THAT NODULES CONTINUED TO SOFTEN AND REGRESS AT 18-MONTH FOLLOW UP, NINE MONTHS AFTER FINAL DOSE

  • STUDY ACHIEVED SECONDARY ENDPOINT OF REDUCTION IN NODULE SIZE AT MULTIPLE TIME POINTS INCLUDING 12 MONTHS

  • THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS IN THE TRIAL

Source text for Eikon: ID:nGNX1SMk2J

Further company coverage: ATNF


((Reuters.Briefs@thomsonreuters.com;))